Chimeric Viral Glycoprotein Vaccine Platform
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current countermeasures lack effective solutions for understanding immunology and pathogenesis of emerging viruses like SARS-COV-2 and Ebola, hindering the development of robust vaccines and treatments.
Innovation Solution
A composition comprising modified viral glycoproteins, such as those from the Filoviridae family, with incorporated antigens like the receptor binding domain (RBD) of SARS-COV-2, displayed on viral vectors like baculovirus, to enhance immune response and facilitate antigen presentation to antigen-presenting cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple viral antigens are combined in a single vaccine composition, then the versatility and breadth of protection against different viral pathogens is improved, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent combines multiple viral antigens (SARS-CoV-2 RBD, Ebola GP, Marburg GP) into a single chimeric glycoprotein construct that can be expressed as one unified molecular entity, thereby providing multi-pathogen protection while simplifying the vaccine composition structure
Solution Approach 2:
The chimeric glycoprotein serves multiple functions simultaneously: it acts as an antigen for SARS-CoV-2, Ebola, and Marburg viruses, and can be displayed on various viral vectors (baculovirus, VSV, adenovirus), making it a universal vaccine platform against multiple viral families
2Adaptability or versatility
If viral glycoproteins are modified to incorporate foreign antigens, then the immune response coverage against multiple pathogens is improved, but the manufacturing precision and structural stability may be compromised
Solution Approach 1:
The patent incorporates foreign viral antigens at specific localized regions of the glycoprotein structure (such as replacing the mucin-like domain or inserting into defined loops), preserving the overall structural integrity and folding of the native glycoprotein while adding immunogenicity against multiple pathogens
Solution Approach 2:
The chimeric glycoprotein functions as a composite molecular structure combining domains from different viral sources (filovirus glycoprotein backbone with coronavirus RBD inserts), maintaining structural stability through careful domain selection and positioning while achieving multi-pathogen recognition
3Ease of operation
If viral vectors are used to display antigens, then the ease of operation and antigen presentation to immune cells is improved, but the reliability and control over antigen expression may be reduced
Solution Approach 1:
The patent uses viral vectors (baculovirus, VSV, adenovirus) as intermediary delivery systems that naturally facilitate antigen presentation to antigen-presenting cells through their established infection mechanisms, while the antigen expression is controlled by defined promoter elements and genetic constructs within the vector system
Data Source
AI summary
Compositions and methods are disclosed for treating and/or preventing viral infections and related pathologies (e.g., Coronavirus and Ebola virus infections and related pathologies). Composition includes those with modified viral glycoproteins, wherein one or more portions of the modified viral glycoproteins are modified to comprise an antigen. Variously, the antigen can include a Coronavirus antigen or an Ebola virus antigen.